Cardiovascular mortality and hospitalisation rates were greatest among heart failure (HF) patients with
reduced ejection fraction (HFrEF) according to clinical trial data. Treatment of heart failure with sodium-glucose
transporter-2 inhibitors (SGLT2i) has recently made significant strides [1]. Even in patients with HFrEF, LV
diastolic dysfunction was a separate predictor of outcome [2]. It is essential to identify structural abnormalities
using echocardiography since they have been linked to prognosis in HF and DM patients [3]. Both diabetic and
non-diabetes patients with HF have had their risk of death and hospital readmission decreased by SGLT2is,
according to large-scale randomised studies and meta-analyses [4]. These are part of the global guidelines for the
treatment of heart failure (HF) at the intermediate assessment level [5]. Some theories suggest that SGLT2is
exerts its cardioprotective effects by reversing cardiac remodelling [6] and restoring systolic and diastolic function